| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03579888 Details | 2021-06-02 Interventional | 1 | 4 | Cyclophosphamid… Fludarabine Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Precursor Cell … Recurrence B Acute Lymphob… Recurrent B Acu… Recurrent Chron… Recurrent Diffu… Recurrent Mantl… Recurrent Non-H… Recurrent Ph-Li… Recurrent Prima… Recurrent Small… Refractory B Ac… Refractory Chro… Refractory Diff… Refractory Mant… Refractory Non-… Refractory Ph-L… Refractory Prim… Refractory Smal… | Study halted prematurely - | |||
| NCT02768558 Details | 2021-06-02 Interventional | 3 | 20 | Etoposide Nivolumab Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | Another treatment found efficacious This study was terminated early due to the reporting of another study which changed this population's standard of care and rendered the control arm obsolete. Eight of the planned 550 analyzable participants were enrolled at the time of termination. | |||
| NCT02065401 Details | 2021-06-02 Interventional | 1 | 0 | Magnesium Hydro… Healthy | This study was withdrawn until the evaluation of the nonclinical rat findings is complete. - | |||
| NCT01927913 2013-000743-33 Details | 2021-06-02 Interventional | 2 | 0 | Deferasirox Hemosiderosis Iron Metabolism… Iron Overload Metabolic Disea… Thalassemia beta-Thalassemi… Beta-thalassemi… Iron Chelation Transfusional H… Transfusional I… | This study was withdrawn until the evaluation of the nonclinical rat findings is complete. - | |||
| NCT04482712 Details | 2021-06-01 Interventional | 1/2 | 0 | Sirolimus Acute Lung Inju… COVID-19 Lung Injury Respiratory Dis… Respiratory Dis… Respiratory Ins… Syndrome Acute Lung Inju… Respiratory Fai… Sars-CoV2 | The study was never submitted to IRB or approved, due to feasibility issues - | |||
| NCT04060407 Details | 2021-06-01 Interventional | 1/2 | 0 | Ipilimumab Nivolumab Melanoma Metastatic Mela… | Business Reasons - | |||
| NCT04483635 Details | 2021-05-28 Interventional | 3 | 34 | Cholecalciferol Vitamin D COVID-19 | A premature discontinuation was recommended by the Data Safety Monitoring Board and agreed upon
by the principal investigator, because the significantly lower recruitment than planned, in the
context of mass vaccination of the target population. - | |||
| NCT04274166 Details | 2021-05-28 Interventional | 2 | 0 | Antibodies, Mon… Pyoderma Pyoderma Gangre… | Contracting never completed, closed the IRB - | |||
| NCT03347526 Details | 2021-05-27 Interventional | 3 | - | Cosyntropin Vigabatrin Spasm Spasms, Infanti… Infantile Spasm | Study on enrollment hold as a precaution per the pharmaceutical company. - | |||
| NCT00945802 Details | 2021-05-27 Interventional | 3 | 5 | BB 1101 Ciprofloxacin Dexamethasone Dexamethasone a… Otitis Otitis Externa Acute Otitis Ex… | - - | |||
| NCT00945646 Details | 2021-05-27 Interventional | 3 | 6 | Dexamethasone Otitis Otitis Externa Otomycosis Acute Fungal Ot… | - - | |||
| NCT04530474 Details | 2021-05-26 Interventional | 3 | 0 | Ivermectin COVID-19 Covid19 | WHO report - | |||
| NCT04373044 Details | 2021-05-26 Interventional | 2 | 6 | Hydroxychloroqu… COVID-19 Laboratory Infe… Symptomatic COV… | The study was terminated after the release of results of ACTT-2 (NCT04401579). - | |||
| NCT02820441 Details | 2021-05-26 Interventional | 4 | 2 | Zopiclone Sleep Apnea Syn… Sleep Apnea, Ce… Ventricular Dys… | - - | |||
| NCT00571519 Details | 2021-05-26 Interventional | 3 | 94 | Metformin Pioglitazone Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo
Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical
development plan with 94 of 2600 planned, randomized participants. - | |||
| NCT00542191 Details | 2021-05-26 Interventional | 2 | 30 | Carboplatin Cyclophosphamid… Doxorubicin Paclitaxel Breast Neoplasm… Triple Negative… Breast Cancer | Enrollment Completed - | |||
| NCT02927405 Details | 2021-05-25 Interventional | 4 | 0 | Gabapentin Pain, Postopera… Postoperative P… | Did not get the study to take off, did not recruit any subjects, and then closed the study. - | |||
| NCT02860117 Details | 2021-05-25 Interventional | 3 | 0 | Ketamine Pain Pain, Burning | change in hospital policy - | |||
| NCT01220128 2010-019909-42 Details | 2021-05-25 Interventional | 2 | 66 | Aromatase Inhib… Carboplatin Cyclophosphamid… Docetaxel Doxorubicin Epirubicin Fluorouracil Paclitaxel Trastuzumab Breast Neoplasm… Neoplasms, Brea… | Study termination due to negative Ph III of another study product from same technology
platform. - | |||
| NCT01376700 2011-000410-18 Details | 2021-05-24 Interventional | 3 | [1 Refs] | 22 | Factor VIII Hemophilia A | It became unlikely to achieve the study objective of 50% reduction over published inhibitor
rates. The Data Monitoring Committee supported this decision. Early termination lead to: -No statistical tests done on risk factors & inhibitor formation. -FVIII consumption by participant not calculated due to large variation in # of EDs. -FVIII-Specific Antibody Isotypes summary statistics not done. |